![](/img/cover-not-exists.png)
PCN96 US COST-EFFECTIVENESS OF PEMBROLIZUMAB COMPARED TO REGORAFENIB AND CABOZANTINIB IN SECOND LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
Upadhyay, N., Mistry, R., Suri, G., Phelps, H., Guest, S., Muston, D.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.220
Date:
May, 2019
File:
PDF, 653 KB
english, 2019